---
title: Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory
  B-cell lymphomas
date: '2023-12-04'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38048694/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20231205170723&v=2.17.9.post6+86293ac
source: Blood
description: 'CD20 is an established therapeutic target in B-cell malignancies. The
  CD20xCD3 bispecific antibody mosunetuzumab has significant efficacy in B-cell non-Hodgkin
  lymphomas (NHL). Since target antigen loss is a recognized mechanism of resistance,
  we evaluated the contribution of CD20 expression to clinical response in patients
  with relapsed and/or refractory NHL in the phase 1/2 GO29781 trial (ClinicalTrials.gov:
  NCT02500407) investigating mosunetuzumab monotherapy. CD20 was studied ...'
disable_comments: true
---
CD20 is an established therapeutic target in B-cell malignancies. The CD20xCD3 bispecific antibody mosunetuzumab has significant efficacy in B-cell non-Hodgkin lymphomas (NHL). Since target antigen loss is a recognized mechanism of resistance, we evaluated the contribution of CD20 expression to clinical response in patients with relapsed and/or refractory NHL in the phase 1/2 GO29781 trial (ClinicalTrials.gov: NCT02500407) investigating mosunetuzumab monotherapy. CD20 was studied ...